Ingo K Mellinghoff

List of Publications by Year
in descending order

90 papers	16,159 citations	71102 41 h-index	49909 87 g-index
91 all docs	91 docs citations	91 times ranked	23255 citing authors

#	Article	IF	Citations
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
2	IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 2012, 483, 474-478.	27.8	1,693
3	Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. New England Journal of Medicine, 2005, 353, 2012-2024.	27.0	1,376
4	An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science, 2013, 340, 626-630.	12.6	1,014
5	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine, 2019, 25, 477-486.	30.7	932
6	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20007-20012.	7.1	927
7	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
8	Challenges to curing primary brain tumours. Nature Reviews Clinical Oncology, 2019, 16, 509-520.	27.6	540
9	Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. PLoS Medicine, 2008, 5, e8.	8.4	499
10	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature, 2019, 565, 654-658.	27.8	361
11	HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell, 2004, 6, 517-527.	16.8	316
12	Differential Sensitivity of Glioma- versus Lung Cancerâ€“Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 458-471.	9.4	304
13	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery, 2017, 7, 1018-1029.	9.4	302
14	Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. PLoS Medicine, 2006, 3, e485.	8.4	298
15	Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. Journal of Clinical Oncology, 2016, 34, 2404-2415.	1.6	297
16	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Translational Medicine, 2015, 7, 274ra17.	12.4	257
17	Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells. Cancer Research, 2006, 66, 7864-7869.	0.9	231
18	MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Reports, 2016, 14, 1590-1601.	6.4	174

#	Article	IF	Citations
19	Ivosidenib in Isocitrate Dehydrogenase 1â€“Mutated Advanced Glioma. Journal of Clinical Oncology, 2020, 38, 3398-3406.	1.6	167
20	Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clinical Cancer Research, 2016, 22, 1837-1842.	7.0	165
21	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncology, 2022, 24, 1935-1949.	1.2	165
22	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology, 2016, 18, 283-290.	1.2	161
23	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood, 2019, 133, 436-445.	1.4	159
24	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery, 2018, 8, 1540-1547.	9.4	138
25	Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis. Cancer Cell, 2009, 16, 44-54.	16.8	132
26	PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research, 2007, 13, 378-381.	7.0	114
27	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clinical Cancer Research, 2021, 27, 4491-4499.	7.0	112
28	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	7.0	107
29	ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State. Cell Reports, 2014, 6, 313-324.	6.4	106
30	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of Clinical Oncology, 2019, 37, 741-750.	1.6	103
31	Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. Cancer Discovery, 2015, 5, 304-315.	9.4	102
32	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6459-6464.	7.1	99
33	Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS Medicinal Chemistry Letters, 2020, 11, 101-107.	2.8	99
34	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2014, 20, 5023-5031.	7.0	89
35	Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. Neuro-Oncology, 2014, 16, viii7-viii13.	1.2	85
36	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸F-(2S,4R)-4-Fluoroglutamine. Radiology, 2018, 287, 667-675.	7.3	80

#	Article	IF	Citations
37	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Molecular Systems Biology, 2017, 13, 914.	7.2	73
38	A kinase-independent function of AKT promotes cancer cell survival. ELife, 2014, 3, .	6.0	70
39	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Investigational New Drugs, 2020, 38, 433-444.	2.6	69
40	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clinical Cancer Research, 2018, 24, 295-305.	7.0	68
41	Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 144, 403-407.	2.9	55
42	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
43	T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status. American Journal of Neuroradiology, 2015, 36, 2256-2261.	2.4	46
44	Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight, 2016, 1, .	5.0	41
45	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of Clinical Oncology, 2018, 36, 1702-1709.	1.6	39
46	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology, 2022, 24, 855-871.	1.2	38
47	Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. Neuro-Oncology, 2022, 24, 1763-1772.	1.2	37
48	Imaging Tumor Burden in the Brain with ⁸⁹Zr-Transferrin. Journal of Nuclear Medicine, 2013, 54, 90-95.	5.0	33
49	Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. Annals of Clinical and Translational Neurology, 2020, 7, 429-436.	3.7	29
50	Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia, 2011, 59, 1205-1212.	4.9	28
51	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. Neuro-Oncology, 2015, 17, 180-188.	1.2	28
52	Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. Neuro-Oncology, 2022, 24, 770-778.	1.2	28
53	A correlative optical microscopy and scanning electron microscopy approach to locating nanoparticles in brain tumors. Micron, 2015, 68, 70-76.	2.2	27
54	The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics, 2002, 3, 603-623.	1.3	26

#	Article	IF	Citations
55	Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization. Bioorganic and Medicinal Chemistry, 2015, 23, 7119-7130.	3.0	26
56	Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. Acta Neuropathologica Communications, 2020, 8, 186.	5.2	26
57	EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nature Communications, 2017, 8, 2035.	12.8	23
58	Pharmacokinetic Assessment of ¹⁸F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer. Journal of Nuclear Medicine, 2020, 61, 357-366.	5.0	23
59	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro-Oncology, 2020, 22, 1822-1830.	1.2	23
60	Will Kinase Inhibitors Make it as Glioblastoma Drugs?. Current Topics in Microbiology and Immunology, 2011, 355, 135-169.	1.1	22
61	Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. Journal of Neuro-Oncology, 2017, 134, 357-362.	2.9	22
62	Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET. Clinical Cancer Research, 2021, 27, 1958-1966.	7.0	21
63	Meningeal lymphatics prime tumor immunity in glioblastoma. Cancer Cell, 2021, 39, 304-306.	16.8	20
64	GCN2 kinase activation by ATP-competitive kinase inhibitors. Nature Chemical Biology, 2022, 18, 207-215.	8.0	19
65	IQGAP1 Controls Tight Junction Formation Through Differential Regulation of Claudin Recruitment. Journal of Cell Science, 2015, 128, 853-62.	2.0	18
66	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. Neuro-Oncology, 2019, 21, vi28-vi29.	1.2	17
67	Clinical Experience of Cerebrospinal Fluidâ€"Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. Journal of Molecular Diagnostics, 2021, 23, 742-752.	2.8	17
68	Tracing cancer networks with phosphoproteomics. Nature Biotechnology, 2010, 28, 1028-1029.	17.5	16
69	Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy. International Journal of Molecular Sciences, 2020, 21, 7193.	4.1	15
70	Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A. Oncotarget, 2019, 10, 6152-6167.	1.8	14
71	Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology, 2016, 5, e1145332.	4.6	13
72	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. Npj Breast Cancer, 2022, 8, 37.	5.2	9

#	Article	IF	Citations
73	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-Oncology, 2022, 24, 1219-1229.	1.2	9
74	Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3940-3950.	6.4	8
75	Cutaneous adverse drug reaction associated with oral temozolomide presenting as dermal and subcutaneous plaques and nodules. JAAD Case Reports, 2015, 1, 286-288.	0.8	7
76	Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. Journal of Clinical Oncology, 2022, 40, 3510-3519.	1.6	7
77	Reply to Parsons: Many tumor types follow the monoclonal model of tumor initiation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E16-E16.	7.1	6
78	PI3K pathway inhibition in GBMâ€"is there a signal?. Neuro-Oncology, 2015, 17, nov124.	1.2	6
79	Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 96-103.	3.8	6
80	Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. Hematology/Oncology Clinics of North America, 2021, 36, 95-111.	2.2	6
81	Why Do Cancer Cells Become â€œAddictedâ€•to Oncogenic Epidermal Growth Factor Receptor?. PLoS Medicine, 2007, 4, e321.	8.4	5
82	Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study. BMC Cancer, 2022, 22, 60.	2.6	5
83	Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2 â€wildtype astrocytomas. Brain Pathology, 2020, 30, 653-660.	4.1	3
84	Noninvasive Imaging of CD4+ T Cells in Humanized Mice. Molecular Cancer Therapeutics, 2022, 21, 658-666.	4.1	3
85	Dissecting Glioma Invasiveness in a 3D-Organotypic Model. Trends in Molecular Medicine, 2017, 23, 776-777.	6.7	2
86	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2074-TPS2074.	1.6	2
87	EPCT-21. NEXT-GENERATION SEQUENCING OF CEREBROSPINAL FLUID FOR CLINICAL MOLECULAR DIAGNOSTICS IN ADOLESCENT AND YOUNG ADULT (AYA) BRAIN TUMOR PATIENTS. Neuro-Oncology, 2021, 23, i51-i51.	1.2	2
88	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunology Research, 2022, 10, 303-313.	3.4	1
89	Reply to â€˜Assembling the brain trust: the multidisciplinary imperative in neuro-oncologyâ€™. Nature Reviews Clinical Oncology, 2019, 16, 522-523.	27.6	0
90	PATH-16. Noninvasive diagnosis of gliomas through CSF cfDNA sequencing in pediatric and adolescent and young adult (AYA) patients. Neuro-Oncology, 2022, 24, i162-i162.	1.2	0